Clinical trials · Pennsylvania
Down Syndrome clinical trials in Pennsylvania
We’re tracking 141 recruiting down syndrome studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT04639830Recruiting
Testing how sleep patterns relate to child brain development
This study looks at how a child’s sleep looks on a sleep-monitoring test and how that relates to brain/learning growth over time. It includes some children without known risks and some children with known developmental or learning risks, to better understand sleep’s role.
Danville, PennsylvaniaAges 6 months–8 years - NCT06440525RecruitingPhase 2
Testing RSLV-132 for Sjögren's disease in women
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
Duncansville, PennsylvaniaAges 18–75 - NCT05905328RecruitingPhase 1/Phase 2
Drug to help prevent and treat cytokine release syndrome
This Phase 1/2 trial tests CTO1681 to help prevent and treat cytokine release syndrome (CRS) in people with DLBCL who are receiving CD19 CAR T-cell therapy. CRS is a potentially serious immune reaction that can happen after CAR T treatment, and this study aims to make that complication less severe or easier to manage.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05995535RecruitingPhase 2
Pregabalin and Lofexidine for Opioid Withdrawal
This study tests whether combining two medications, pregabalin and lofexidine, can help people stop using opioids by easing withdrawal symptoms. It's for adults who use opioids heavily and want to switch to a non-addictive blocker medication.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05905926Enrolling by invitationPhase 3
Tenapanor safety study for teens with constipation-predominant IBS
This trial checks the safety of tenapanor in children and teens (ages 6 to under 18) with IBS-C. It is only for people who finished a previous related study and agreed to continue follow-up.
Scottdale, PennsylvaniaAges 6–18 - NCT05654922RecruitingPhase 3
Prevent lung transplant airways scarring with ARINA-1
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Philadelphia, PennsylvaniaAges 18–75 - NCT07276035Recruiting
Brain-stomach circuits in chronic nausea
This study looks at how the brain and stomach communicate in people with chronic nausea. It uses a noninvasive brain stimulation method called TMS to understand brain activity. You may qualify if you have chronic nausea or are a healthy volunteer.
Pittsburgh, PennsylvaniaAges 21–60 - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05701917Recruiting
Clot-busting device versus blood thinners for leg clot
This study compares a clot-removal device (ClotTriever) plus standard care versus standard blood thinners alone for a deep vein clot in the leg. It aims to see which approach better improves leg symptoms and outcomes.
Erie, PennsylvaniaAges 18 years+ - NCT03533985Recruiting
Music therapy for newborns in the NICU with withdrawal symptoms
This study looks at whether music therapy can help infants who are born with neonatal abstinence syndrome (withdrawal symptoms after birth). It may support comfort, bonding, or overall newborn well-being while they’re in the NICU.
Philadelphia, PennsylvaniaAges 6 months+ - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03779854RecruitingPhase 2
Preventing graft-versus-host disease in kids after stem cell transplant
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Pittsburgh, PennsylvaniaAges 6 months–26 years - NCT02967068Recruiting
Share your study tissue for future research
This study is a “tissue repository” that collects and stores leftover tissue from other approved VCRC studies. If you already took part in one of those studies, you may be able to let researchers use your tissue to help answer future questions.
Pittsburgh, PennsylvaniaAges Any age - NCT03418857RecruitingPhase 1/Phase 2
Probiotics for weight- and blood-sugar–related gut health
This trial tests whether taking probiotics can improve gut health in people with early metabolic problems related to extra body fat, cholesterol, blood pressure, or blood sugar. It’s a Phase 1/2 study, meaning safety and early effectiveness are being tested.
University Park, PennsylvaniaAges 55–75 - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Philadelphia, PennsylvaniaAges Any age - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Philadelphia, PennsylvaniaAges 18–75 - NCT04064060RecruitingPhase 3
Long-term safety follow-up for luspatercept study participants
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04528355Recruiting
Study of hospital data after stem cell transplant for non-cancer illness
This study collects medical information from people with certain non-cancer conditions who receive a stem cell transplant. It may help doctors better understand transplant outcomes and care, since the study focuses on data collection rather than adding new treatment.
Pittsburgh, PennsylvaniaAges 2 months–60 years - NCT04545424RecruitingPhase 2
Testing cooling treatment for severe lung failure in ICU patients
This trial tests whether therapeutic cooling (hypothermia) can improve outcomes in people with ARDS, a serious lung condition causing breathing failure. It may help by reducing harmful inflammation and lung injury, but eligibility is time-sensitive and requires ICU monitoring.
Philadelphia, PennsylvaniaAges 18–85 - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Pittsburgh, PennsylvaniaAges 1–30 - NCT04715399Recruiting
Research study collecting data for neurodegenerative diseases
This study collects health information from people with neurodegenerative diseases, some family members, and healthy controls to help researchers better understand these conditions. It may help future diagnosis and research, and participation may include noninvasive checks and other procedures depending on your situation.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04771130RecruitingPhase 1/Phase 2
Study of BGB-11417 for blood cancers
This early-phase study tests BGB-11417 in people with certain bone-marrow (blood) cancers such as AML, MDS, or MDS/MPN. The goal is to find out how the medicine works and whether it can control the cancer.
Pittsburgh, PennsylvaniaAges 18 years+
Down Syndrome trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting down syndrome studies listed above.
- University of Pennsylvania · 5 studies
- Thomas Jefferson University Hospital · 4 studies
- University of Pittsburgh Medical Center · 3 studies
- UPMC Children's Hospital of Pittsburgh · 3 studies
- Geisinger Medical Center · 2 studies
- Temple University Hospital · 2 studies
- UPMC Hillman Cancer Center · 2 studies
- Allegheny General Hospital
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in Pennsylvania?
- Yes. We're currently tracking 141 recruiting down syndrome studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.